TMEM106B Genetic Modifiers in Frontotemporal Dementia
Overview
TMEM106B (Transmembrane Protein 106B) has emerged as a critical genetic modifier in frontotemporal dementia (FTD), particularly in individuals carrying pathogenic variants in the GRN (progranulin) gene[@lysosomal]. This page synthesizes current knowledge of TMEM106B haplotypes, their mechanisms of action, and therapeutic implications.
TMEM106B Biology
TMEM106B is a lysosomal transmembrane protein encoded by the TMEM106B gene located on chromosome 7p21.3. It is highly expressed in the brain, particularly in [microglia](/cell-types/microglia-neuroinflammation) and [neurons](/entities/neurons), and localizes to lysosomal membranes where it functions as an ion channel or transporter[@divergenta].
Normal Function
Lysosomal membrane protein involved in acidification and trafficking
Regulates lysosomal function and [autophagy](/entities/autophagy)
Expressed predominantly in microglia and neurons
May play a role in progranulin (GRN) trafficking and processing
Structural Features
TMEM106B forms amyloid fibrils in human brains in an age-dependent manner[@divergent], and these fibrils are found in frontotemporal lobar degeneration (FTLD)-TDP-43 brains[@diseasemodifying]. The protein can form homotypic fibrils across diverse neurodegenerative diseases[@truncation].
TMEM106B Haplotypes and FTD Risk
...
TMEM106B Genetic Modifiers in Frontotemporal Dementia
Overview
TMEM106B (Transmembrane Protein 106B) has emerged as a critical genetic modifier in frontotemporal dementia (FTD), particularly in individuals carrying pathogenic variants in the GRN (progranulin) gene[@lysosomal]. This page synthesizes current knowledge of TMEM106B haplotypes, their mechanisms of action, and therapeutic implications.
TMEM106B Biology
TMEM106B is a lysosomal transmembrane protein encoded by the TMEM106B gene located on chromosome 7p21.3. It is highly expressed in the brain, particularly in [microglia](/cell-types/microglia-neuroinflammation) and [neurons](/entities/neurons), and localizes to lysosomal membranes where it functions as an ion channel or transporter[@divergenta].
Normal Function
Lysosomal membrane protein involved in acidification and trafficking
Regulates lysosomal function and [autophagy](/entities/autophagy)
Expressed predominantly in microglia and neurons
May play a role in progranulin (GRN) trafficking and processing
Structural Features
TMEM106B forms amyloid fibrils in human brains in an age-dependent manner[@divergent], and these fibrils are found in frontotemporal lobar degeneration (FTLD)-TDP-43 brains[@diseasemodifying]. The protein can form homotypic fibrils across diverse neurodegenerative diseases[@truncation].
TMEM106B Haplotypes and FTD Risk
Genome-wide association studies (GWAS) identified a common variant at 7p21.3 (the TMEM106B locus) as associated with increased risk for FTLD with TDP-43 inclusions[@lysosomal]. Subsequent research identified two major haplotypes:
The Protective Haplotype (H2)
The TMEM106B H2 haplotype (protective variant) is associated with:
Reduced risk of FTD in GRN mutation carriers
Later age of onset (approximately 5-10 years later)
Slower disease progression
Less severe brain atrophy on MRI
The Risk Haplotype (H1)
The TMEM106B H1 haplotype (risk variant) is associated with:
Increased FTD risk, particularly in GRN carriers
Earlier age of onset
More severe TDP-43 pathology
Reduced cerebrospinal fluid progranulin levels
Impact on GRN Carriers
Haploinsufficiency Mechanisms
TMEM106B haplotypes influence FTD pathogenesis through several molecular mechanisms:
Lysosomal dysfunction: The H1 risk haplotype impairs lysosomal acidification and trafficking[@divergenta]
Altered progranulin trafficking: TMEM106B affects progranulin processing and secretion
TDP-43 aggregation: Modulates the propensity for TDP-43 to form aggregates
Microglial activation: Influences neuroinflammatory responses in microglia
Clinical Effects in GRN Mutation Carriers
| Factor | H1/H1 (Risk) | H2/H2 (Protective) | |--------|--------------|---------------------| | Age of Onset | ~5-10 years earlier | Later onset | | Disease Severity | More severe | Milder phenotype | | Brain Atrophy | Greater, especially frontal/temporal | Less atrophy | | Survival | Shorter | Longer | | CSF Progranulin | Lower levels | Higher levels |
Impact on MAPT Carriers
While TMEM106B has been most extensively studied in GRN mutation carriers, emerging evidence suggests it may also modify disease in individuals with [MAPT](/proteins/tau) mutations:
Evidence for MAPT Modification
TMEM106B variants may influence age at onset in MAPT mutation carriers
The H1 haplotype associated with earlier onset in some MAPT families
May affect the pattern of tau pathology distribution
Mechanistic Considerations
Both MAPT and TMEM106B affect lysosomal function
Potential interaction between tau processing and TMEM106B biology
May influence the transition from primary tauopathy to TDP-43 comorbidity
TDP-43 Pathology Modulation
TMEM106B haplotypes significantly influence TDP-43 pathology in FTD[^8]:
H1 carriers show increased TDP-43 aggregation in neurons and glia
This section highlights recent publications relevant to this disease.
[Lysosomal escape and TMEM106B fibrillar core determine TDP-43 seeding outcomes.](https://pubmed.ncbi.nlm.nih.gov/41497595/) (2025 Dec 22) - bioRxiv : the preprint server for biology
[Divergent and convergent TMEM106B pathology in murine models of neurodegeneration and human disease.](https://pubmed.ncbi.nlm.nih.gov/40783546/) (2025 Aug 9) - Acta neuropathologica communications
[Disease-modifying effects of TMEM106B in genetic frontotemporal dementia: a longitudinal GENFI study.](https://pubmed.ncbi.nlm.nih.gov/40260680/) (2025 Aug 1) - Brain : a journal of neurology
[Truncation mutation of CHMP2B disrupts late endosome function but reduces TDP-43 aggregation through HSP70 upregulation.](https://pubmed.ncbi.nlm.nih.gov/40316175/) (2025 Jul) - Neurochemistry international
[Divergent and Convergent TMEM106B Pathology in Murine Models of Neurodegeneration and Human Disease.](https://pubmed.ncbi.nlm.nih.gov/39606446/) (2024 Nov 19) - Research square